Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors

Arthritis Care and Research

Volumn 53, Issue 3, 2005, Pages 452-459

  Afeltra, Antonella ^a   Vadacca, Marta ^a   Conti, Laura ^b   Galluzzo, Sara ^a   Mitterhofer, Anna P ^c   Ferri, Giovanni M ^c   Del Porto, Flavia ^c   Caccavo, Domenico ^d   Gandolfo, Giuseppe M ^c   Amoroso, Antonio ^c  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Istituti Fisioterapici Ospitalieri Rome   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Risk factors; Systemic lupus erythematosus; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; CARDIOLIPIN ANTIBODY; D DIMER; FIBRINOGEN; HOMOCYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; MUTANT PROTEIN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADOLESCENT; ADULT; ANAMNESIS; ANTIBODY TITER; ARTERY THROMBOSIS; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC RISK; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTITHROMBINS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HOMOCYSTEINE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; PROTEIN C; PROTHROMBIN; RISK FACTORS; THROMBOSIS;

EID: 20444378185     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21172     Document Type: Article

References (42)

1. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000;160:2042-8.
2. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
3. Qushmaq K, Esdaile J, Devine DV. Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. Arthritis Care Res 1999;12:212-9.
4. Kiraz S, Ertenli I, Benekli M, Haznedaroglu IC, Calguneri M, Celik I et al. Clinical significance of haemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999;8:737-41.
5. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996;25:191-3.
6. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996;39:9-22.
7. Coppola A, Davi G, de Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000;26:243-54.
8. Blom HJ. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost 2000;26:227-32.
9. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
10. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002;87:1095-108.
11. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996;76:651-62.
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
14. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
15. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med 1998;338:1042-50.
16. Brandt JT, Triplett DA, Alving B, Scharrer I, and the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185-90.
17. Harris EN. Special report: the Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990;94:476-84.
18. Torresan M, Machado TF, Siquiera LH, Ozelo MC, Arruda VR, Annichino-Bizzacchi JM. The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. Blood Coagul Fibrinolysis 2000;11:679-82.
19. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991;66:520-4.
20. Amoroso A, Mitterhofer AP, Del Porto F, Garzia P, Ferri GM, Galluzzo S, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003;64:265-73.
21. Musial J, Swadzba J, Szczeklik A. Adaptative mechanisms counterbalancing enhanced thrombinogenesis in antiphospholipid syndrome. Thromb Res 1998;90:93-4.
22. Tomas JF, Alberca I, Tabernero MD, Cordero M, Del Pino-Montes J, Vicente V. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1998;25:57-62.
23. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67.
24. Oosting JD, Derkesen RH, Bobbink IW, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
25. Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol 1998;25:1737-42.
26. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
27. Refai TM, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 2002;21:457-61.
28. Hampton KK, Preston FE, Greaves M. Resistance to activated protein C [letter]. N Engl J Med 1994;331:130.
29. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002;118:577-83.
30. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
31. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111:1223-9.
32. Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996;7:344-8.
33. Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falco C. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997;130:202-8.
34. Picillo U, De Lucia D, Palatiello E, Scuotto A, Marcialis MR, Pezzella S, et al. Association of primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol 1998;25:1232-4.
35. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001;97:844-9.
36. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995;74:797-8.
37. Potzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Muller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995;125:56-65.
38. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997;77:332-5.
39. Petri M. Management of thrombosis in antiphospholipid antibody syndrome. Rheum Dis Clin North Am 2001;27:633-42.
40. Alarcon-Segovia D. Antiphospholipid syndrome within systemic lupus erythematosus. Lupus 1994;3:289-91.
41. Roubey RA. Systemic lupus erythematosus, hypercoagulable states, and antiphospholipid antibodies. Arthritis Care Res 1999;12:155-6.
42. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.